Last reviewed · How we verify

NCT06641531

Prevalence of Abnormal Pap Smear

Recruiting now Last updated 15 October 2024
What this trial tests

trial testing Screening pap smear test in Cervix Cancer in 300 participants. Currently enrolling.

Timeline
1 October 2024
Primary endpoint
1 April 2025
1 April 2025

Quick facts

Lead sponsorSohag University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment300
Start date1 October 2024
Primary completion1 April 2025
Estimated completion1 April 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Sohag University

Who can join

Adults 21 to 60, female only, with Cervix Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate prevalence of abnormal Pap smear among sexually active women of reproductive age attending sohag university hospital outpatient clinic.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cervix Cancer

Currently open trials in the same condition.

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06641531.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing